3/27
08:00 am
fdmt
4DMT to Participate in Upcoming Investor Conferences
Medium
Report
4DMT to Participate in Upcoming Investor Conferences
3/24
02:03 am
fdmt
4D Molecular Therapeutics, Inc. (NASDAQ: FDMT) had its "sell (e+)" rating re-affirmed by analysts at Weiss Ratings.
Medium
Report
4D Molecular Therapeutics, Inc. (NASDAQ: FDMT) had its "sell (e+)" rating re-affirmed by analysts at Weiss Ratings.
3/10
01:15 pm
fdmt
4D Molecular Therapeutics, Inc. (NASDAQ: FDMT) had its price target lowered by analysts at Bank of America Co. from $42.00 to $40.00. They now have a "buy" rating on the stock.
Low
Report
4D Molecular Therapeutics, Inc. (NASDAQ: FDMT) had its price target lowered by analysts at Bank of America Co. from $42.00 to $40.00. They now have a "buy" rating on the stock.
3/10
08:07 am
fdmt
4DMT Announces First Patients Enrolled in 4FRONT-1 Phase 3 Clinical Trial Evaluating 4D-150 in Wet AMD [Yahoo! Finance]
Medium
Report
4DMT Announces First Patients Enrolled in 4FRONT-1 Phase 3 Clinical Trial Evaluating 4D-150 in Wet AMD [Yahoo! Finance]
3/10
08:00 am
fdmt
4DMT Announces First Patients Enrolled in 4FRONT-1 Phase 3 Clinical Trial Evaluating 4D-150 in Wet AMD
Medium
Report
4DMT Announces First Patients Enrolled in 4FRONT-1 Phase 3 Clinical Trial Evaluating 4D-150 in Wet AMD
3/8
01:33 am
fdmt
4D Molecular Therapeutics, Inc. (NASDAQ: FDMT) had its "sell (d-)" rating re-affirmed by analysts at Weiss Ratings.
Medium
Report
4D Molecular Therapeutics, Inc. (NASDAQ: FDMT) had its "sell (d-)" rating re-affirmed by analysts at Weiss Ratings.
3/6
12:29 pm
fdmt
Gene Editing Collaboration and Licensing Terms and Agreements Trends Report and Directory 2016-2024 [Yahoo! Finance]
Low
Report
Gene Editing Collaboration and Licensing Terms and Agreements Trends Report and Directory 2016-2024 [Yahoo! Finance]
3/4
08:03 am
fdmt
4D Molecular Therapeutics, Inc. (NASDAQ: FDMT) had its price target lowered by analysts at Chardan Capital from $30.00 to $28.00. They now have a "buy" rating on the stock.
Medium
Report
4D Molecular Therapeutics, Inc. (NASDAQ: FDMT) had its price target lowered by analysts at Chardan Capital from $30.00 to $28.00. They now have a "buy" rating on the stock.
3/3
11:07 am
fdmt
4D Molecular Therapeutics, Inc. (NASDAQ: FDMT) had its price target lowered by analysts at Royal Bank of Canada from $39.00 to $35.00. They now have an "outperform" rating on the stock.
Medium
Report
4D Molecular Therapeutics, Inc. (NASDAQ: FDMT) had its price target lowered by analysts at Royal Bank of Canada from $39.00 to $35.00. They now have an "outperform" rating on the stock.
3/3
08:10 am
fdmt
4D Molecular Therapeutics, Inc. (NASDAQ: FDMT) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $36.00 price target on the stock.
Medium
Report
4D Molecular Therapeutics, Inc. (NASDAQ: FDMT) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $36.00 price target on the stock.
3/2
07:27 am
fdmt
4D Molecular Therapeutics Full Year 2024 Earnings: Misses Expectations [Yahoo! Finance]
High
Report
4D Molecular Therapeutics Full Year 2024 Earnings: Misses Expectations [Yahoo! Finance]
2/28
04:05 pm
fdmt
4DMT Reports Full Year 2024 Financial Results, Operational Highlights and Expected Upcoming Milestones
Medium
Report
4DMT Reports Full Year 2024 Financial Results, Operational Highlights and Expected Upcoming Milestones
2/20
02:31 am
fdmt
4D Molecular Therapeutics, Inc. (NASDAQ: FDMT) had its "sell (d-)" rating re-affirmed by analysts at Weiss Ratings.
Low
Report
4D Molecular Therapeutics, Inc. (NASDAQ: FDMT) had its "sell (d-)" rating re-affirmed by analysts at Weiss Ratings.
2/19
08:00 am
fdmt
4DMT to Participate in Upcoming Investor Conferences
Medium
Report
4DMT to Participate in Upcoming Investor Conferences
2/18
02:41 pm
fdmt
4D Molecular Therapeutics: A Smart Bet On Long-Term VEGF Suppression [Seeking Alpha]
Low
Report
4D Molecular Therapeutics: A Smart Bet On Long-Term VEGF Suppression [Seeking Alpha]
2/11
04:43 pm
fdmt
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of 4D Molecular Therapeutics, Inc. - FDMT
Low
Report
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of 4D Molecular Therapeutics, Inc. - FDMT
2/11
08:09 am
fdmt
4D Molecular Therapeutics, Inc. (NASDAQ: FDMT) had its price target lowered by analysts at Chardan Capital from $39.00 to $30.00. They now have a "buy" rating on the stock.
High
Report
4D Molecular Therapeutics, Inc. (NASDAQ: FDMT) had its price target lowered by analysts at Chardan Capital from $39.00 to $30.00. They now have a "buy" rating on the stock.
2/10
08:00 am
fdmt
4D Molecular Therapeutics, Inc. (NASDAQ: FDMT) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $36.00 price target on the stock.
High
Report
4D Molecular Therapeutics, Inc. (NASDAQ: FDMT) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $36.00 price target on the stock.
2/8
02:30 pm
fdmt
4DMT Presents Positive 52-Week Results from Phase 2b Cohort of PRISM Wet AMD Study and Long-term Durability Data Supporting 4D-150 4FRONT Global Registration Program
High
Report
4DMT Presents Positive 52-Week Results from Phase 2b Cohort of PRISM Wet AMD Study and Long-term Durability Data Supporting 4D-150 4FRONT Global Registration Program
2/4
03:55 pm
fdmt
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of 4D Molecular Therapeutics, Inc. - FDMT
Low
Report
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of 4D Molecular Therapeutics, Inc. - FDMT
2/4
02:07 am
fdmt
4D Molecular Therapeutics, Inc. (NASDAQ: FDMT) had its "sell (d-)" rating re-affirmed by analysts at Weiss Ratings.
Low
Report
4D Molecular Therapeutics, Inc. (NASDAQ: FDMT) had its "sell (d-)" rating re-affirmed by analysts at Weiss Ratings.
2/1
10:00 am
fdmt
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of 4D Molecular Therapeutics, Inc. - FDMT
Medium
Report
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of 4D Molecular Therapeutics, Inc. - FDMT
1/30
12:00 pm
fdmt
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of 4D Molecular Therapeutics, Inc. - FDMT
Medium
Report
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of 4D Molecular Therapeutics, Inc. - FDMT
1/29
08:00 am
fdmt
4DMT Announces Corporate Webcast to Review Interim 52-week Results from the Phase 2b Cohort of PRISM in a Broad Wet AMD Population
Medium
Report
4DMT Announces Corporate Webcast to Review Interim 52-week Results from the Phase 2b Cohort of PRISM in a Broad Wet AMD Population
1/28
12:00 pm
fdmt
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of 4D Molecular Therapeutics, Inc. - FDMT
Low
Report
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of 4D Molecular Therapeutics, Inc. - FDMT